15.02.2018 17:30:00
|
Sartorius Stedim Biotech S.A.: Resolutions by the Board of Directors
Regulatory News:
The Board of Directors of Sartorius Stedim Biotech S.A. (SSB) (Paris:DIM) resolved at its most recent meeting to submit a proposal to the Annual General Shareholders' Meeting on April 3, 2018, to pay a dividend for fiscal 2017 of €0.46 per share. The previous year’s dividend was €0.42. Under this proposal, the total profit distributed would rise by 9.5% from €38.7 million to €42.4 million.
Furthermore, the Board of Directors will propose to the Annual General Shareholders´ Meeting to ratify the cooptation of Dr. Lothar Kappich as Director of the company. In September 2017, Lothar Kappich replaced Professor Arnold Picot, who passed away on July 9, 2017. Kappich's directorship would last for one more year.
In addition, the Board of Directors will submit a proposal to approve the renewal of the appointments of Susan Dexter and Anne-Marie Graffin as Directors, each for a three-year term.
This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks und uncertainties.
A profile of Sartorius Stedim Biotech
Sartorius Stedim
Biotech is a leading international supplier of products and services
that enable the biopharmaceutical industry to develop and manufacture
drugs safely and efficiently. As a total solutions provider, Sartorius
Stedim Biotech offers a portfolio covering nearly all steps of
biopharmaceutical manufacture. The company focuses on single-use
technologies and value-added services to meet the rapidly changing
technology requirements of the industry it serves. Headquartered in
Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of
Euronext Paris. With its own manufacturing and R&D sites in Europe,
North America and Asia and an international network of sales companies,
Sartorius Stedim Biotech has a global reach. In 2017, the company
employed approx. 5,100 people, and earned sales revenue of €1,081.0
million according to preliminary figures.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005853/en/
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius Stedim Biotechmehr Nachrichten
17.10.24 |
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 (EQS Group) | |
16.10.24 |
Ausblick: Sartorius Stedim Biotech zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
04.10.24 |
ANALYSE-FLASH: RBC lässt Sartorius Stedim Biotech auf 'Outperform' (dpa-AFX) | |
03.10.24 |
ANALYSE-FLASH: Goldman startet Sartorius Stedim Biotech mit 'Buy', Ziel 225 Euro (dpa-AFX) | |
02.10.24 |
Erste Schätzungen: Sartorius Stedim Biotech gewährt Anlegern Blick in die Bücher (finanzen.net) | |
18.07.24 |
Half-year results 2024 of SartoriusStedimBiotech (EQS Group) | |
18.07.24 |
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024 (EQS Group) | |
18.07.24 |
Ausblick: Sartorius Stedim Biotech vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Sartorius Stedim Biotechmehr Analysen
22.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
17.10.24 | Sartorius Stedim Biotech Buy | Goldman Sachs Group Inc. | |
03.10.24 | Sartorius Stedim Biotech Buy | Goldman Sachs Group Inc. | |
03.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
02.09.24 | Sartorius Stedim Biotech Outperform | RBC Capital Markets |